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Cell growth inhibition by the Mad/Max complex through
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Background: The organization of chromatin is crucial for the regulation of gene
expression. In particular, both the positioning and properties of nucleosomes
influence promoter-specific transcription. The acetylation of core histones has
been suggested to alter the properties of nucleosomes and affect the access of
DNA-binding transcriptional regulators to promoters. A recently identified
mammalian histone deacetylase (HD1) shows homology to the yeast Rpd3
protein, which together with Sin3 affects the transcription of several genes.
Mammalian Sin3 proteins interact with the Mad components of the
Myc/Max/Mad network of cell growth regulators. Mad/Max complexes may
recruit mammalian Rpd3-like enzymes, therefore, directing histone deacetylase
activity to promoters and negatively regulating cell growth. 
Results: We report the identification of a tetrameric complex composed of Max,
Mad1, Sin3B and HD1. This complex has histone deacetylase activity which
can be blocked by the histone deacetylase inhibitors trichostatin A and sodium
butyrate. The inhibition of cell growth by Mad1 is enhanced by Sin3B and HD1,
as measured by colony formation assays. Furthermore, a Mad1-induced block
of S-phase progression can be overcome by trichostatin A, as shown in
microinjection experiments. 
Conclusions: The recruitment of a histone deacetylase by sequence-specific
DNA-binding proteins provides a mechanism by which the state of acetylation
of histones in nucleosomes and hence the activity of specific promoters can be
influenced. The finding that Mad/Max complexes interact with Sin3 and HD1 in
vivo suggests a model for the role of Mad proteins in antagonizing the function
of Myc proteins.
Background
The Myc family of proto-oncoproteins plays a key role in
the regulation of cell growth, differentiation and apoptosis
(for review, see [1–3]). To exert its function, c-Myc has to
heterodimerize with Max [4–8]. Members of the Mad
family of proteins also heterodimerize with Max [9–11],
and so Max is regarded as the central component of the
Myc/Max/Mad network. All these proteins belong to the
bHLHZip class of DNA-binding molecules, characterized
by a basic DNA-binding region and a dimerization domain
composed of a helix–loop–helix motif and a leucine zipper
motif. The expression pattern and functional characteriza-
tion of Mad proteins (Mad1, Mxi1, Mad3 and Mad4)
suggest that they are negative regulators of cell growth:
Mad proteins inhibit the transformation of rat embryo
fibroblasts by c-Myc and Ha-Ras, negatively regulate
reporter gene transcription, and interfere with S-phase
progression [9,11–16]. Besides the bHLHZip domain, an
amino-terminal domain of the Mad proteins, the Sin3-
interaction domain, is essential for these regulatory func-
tions [11,17,18]. Sin3 has been shown to interact with Mad
proteins and, when expressed as a fusion protein with a
DNA-binding domain, to repress gene transcription
[19–23]; these observations suggest that Sin3 is important
for mediating Mad effects, although the molecular basis of
this repression is presently unknown. 
Chromatin structure is a critical determinant in the
regulation of promoter activity [24–26]. Nucleosomes,
which contain approximately 150 base-pairs of DNA
wrapped around a core histone octamer, can affect trans-
cription both by their specific positioning on the DNA and
by modifications of their histone components. The acety-
lation of the amino-terminal tails of core histones is an
important reversible post-translational modification
[25,27–30], and it has been suggested that such acetylation
may affect the interaction between histones and DNA,
influencing nucleosome compaction. This in turn could
regulate the access of proteins to DNA or modify nucle-
osome mobility. For example, histone acetylation facili-
tates the binding of TFIIIA to nucleosomal templates
[31], and the removal of the amino termini of core histones
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by limited proteolysis increases the accessibility of tran-
scription factors to nucleosomes [31,32].
Regulation by acetylation is not likely to be a simple
quantitative effect. Studies with antibodies that recognize
histone H4 acetylated at specific lysine residues have
shown that the different isoforms of H4 have distinct
patterns of distribution on chromosomes [33–35]. In addi-
tion, different histone acetyltransferases (HATs) have
different specificities regarding the histone(s) and the
site(s) modified ([36–38] and A. Lusser, G. Brosch, G.
Lòpez-Rodas and P.L., unpublished observations). These
findings indicate that the amino termini of core histones,
together with their specific acetylation, play an important
role in regulating gene transcription. 
The molecular characterization of HATs has strengthened
the argument that acetylation is linked to activation of
gene transcription. Several proteins that have been identi-
fied previously as positive transcriptional regulators also
possess HAT activity; these proteins include the transcrip-
tional adaptor protein GCN5, P/CAF, the co-activators
CBP and p300, and TAFII250, a component of the general
transcription factor TFIID [37–42]. HAT activity may
therefore be part of, and influence the activity of, the
RNA polymerase II holoenzyme. Furthermore, transcrip-
tion factors such as CREB or c-Myb, which recruit CBP
and/or p300 [43–47], could bring HATs to promoters and
thereby modulate the acetylation pattern of histones,
which in turn will alter chromatin structure. This could
then affect the accessibility of additional transcription
factors to DNA-binding sites, resulting in efficient gene
expression. 
Whereas a considerable amount of information is available
on the functional role of HATs, comparably little has been
published on the role of histone deacetylases. A mam-
malian histone deacetylase (HD1) was identified recently,
and the gene has been cloned [48]. The catalytic subunit
of this enzyme has 60% identity to the protein encoded by
the yeast RPD3 gene [48]. Yeast Rpd3 and Sin3 function
in the same genetic pathway for the transcriptional regula-
tion of a number of different genes, and it has been
suggested that these two proteins interact directly
[29,49,50]. Thus, mammalian Sin3 proteins may function
as targeting subunits for histone deacetylases, a concept
which is consistent with the identification of four paired
amphipathic helix (PAH) motifs in Sin3, suggested to
provide surfaces for protein–protein interaction [51]. The
second PAH motif of Sin3 binds to the Sin3-interaction
domain of Mad proteins and of Mnt, a recently identified
novel interaction partner of Max, as shown by yeast two-
hybrid and in vitro analyses [11,17,18,52].
Three lines of evidence therefore led to the hypothesis
that Mad/Max proteins may recruit HD1 via Sin3 in a
mammalian system: first, an interaction between Mad1
and Max has been shown previously in vivo [53]; second,
an interaction between Sin3 proteins, encoded by the two
related genes sin3A and sin3B, and Mad proteins has been
shown in the yeast two-hybrid system and in in vitro inter-
action assays [11,17,18]; and third, yeast Sin3 and Rpd3
function in the same genetic pathway, suggesting that
they interact [29]. Here, we have tested whether Sin3
interacts with the Mad/Max complex in mammalian cells
and, furthermore, whether the trimeric complex
Max/Mad/Sin3 can recruit HD1. We have identified a
Max/Mad/Sin3B/HD1 complex which has histone
deacetylase activity. Using colony formation and S-phase
progression assays, we show that the recruitment of
histone deacetylase activity by Mad/Max is functionally
relevant. 
Results
In order to determine whether Sin3B interacts with Mad1
in vivo and whether HD1 binds to a Max/Mad1/Sin3B
complex, COS7 cells were transiently transfected with
cDNAs encoding these four proteins, and complexes were
co-immunoprecipitated from whole cell lysates. Using
either polyclonal or monoclonal anti-Mad1 antibodies, both
Max and Sin3B were identified in the immunoprecipitates
(Fig. 1 and data not shown). Similarly, Sin3B was detected
in anti-Max immunoprecipitates but not in immunoprecip-
itates using control antibodies (data not shown, see also
below). Together, these findings reveal that Sin3B can
interact with the Mad1/Max complex in vivo. 
The HD1 protein was also detected specifically in anti-
Mad1 immunoprecipitates (Fig. 1), and these immuno-
precipitated complexes contained histone deacetylase
activity, as measured by the release of radioactive acetate
from histones labelled in vivo (Fig. 2a). Using the mono-
clonal antibody 5F4, which recognizes a carboxy-terminal
epitope of Mad1 (Fig. 2b,c), we recovered histone deacety-
lase activity from cells expressing Max, Mad1, Sin3B and
HD1 (Fig. 2a). In the absence of Mad1, Sin3 or HD1, only
little or background histone deacetylase activity was
detectable in the immunoprecipitates.
When the cDNA encoding Mad1 was replaced with that
encoding Mad1∆N — a variant without the amino-
terminal 56 amino acids, a region which includes the Sin3-
interaction domain [14] — in the transient transfections,
no histone deacetylase activity was co-immunoprecipi-
tated from the cell lysates. This observation is consistent
with the role of the Mad1 Sin3-interaction domain in the
recruitment of Sin3B. Histone deacetylase activity was
co-immunoprecipitated from cells expressing Mad1∆BR —
a variant lacking the basic region, responsible for DNA-
binding — however, and so the ability to bind to DNA
does not appear to be a prerequisite for complex formation
(Fig. 2a). No histone deacetylase activity was detected in
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immunoprecipitations from cells expressing Mad1∆C, a
protein which was not recognized by the anti-Mad
monoclonal antibody 5F4 (Fig. 2b,c). When the
monoclonal antibody 5C9, which recognized an amino-ter-
minal epitope of Mad1 (Fig. 2b,c), was used instead of 5F4,
histone deacetylase activity was co-immunoprecipitated
from cell lysates expressing Mad1∆C or wild-type Mad1
(Fig. 2a). These findings demonstrate that Mad1 can asso-
ciate with functional HD1 in vivo in the presence of Sin3B. 
As Mad1 has been shown to form a complex with Max in
vivo, we tested whether histone deacetylase activity could
be detected in anti-Max immunoprecipitates. When HD1,
Max, Mad1 and Sin3B were expressed together, high levels
of histone deacetylase activity were detected in the
immunoprecipitates (Fig. 3a). In the absence of Sin3B
and/or HD1, low levels of histone deacetylase activity were
observed; this activity is likely to be due to the binding of
endogenous Sin3B and HD1 or other Rpd3-related
enzymes. In contrast, in the absence of Mad1, only back-
ground activity was measured, consistent with the low-level
expression reported for all known Mad proteins. No activity
was found when pre-immune serum was used for the
immunoprecipitations. The histone deacetylase activity of
the anti-Max immunoprecipitates was completely inhibited
in the presence of Na-butyrate or trichostatin A (TSA) (Fig.
3a), which are inhibitors of histone deacetylases [54]. Thus,
our data provide evidence for a cell-derived tetrameric
complex composed of Max/Mad1/Sin3B/HD1 which con-
tains histone deacetylase activity, with Sin3B mediating the
interaction between Mad1 and HD1. 
Max has also been shown to heterodimerize with
members of the Mad family other than Mad1, including
Mad4 [11]. Histone deacetylase activity was detected in
anti-Max immunoprecipitates from cells expressing Mad4
together with Max, Sin3B and HD1 (Fig. 3b), suggesting
that association with HD1 via Sin3B is a general attribute
of Mad proteins — consistent with the findings that all
Mad proteins contain Sin3-interaction domains and associ-
ate with Sin3. The lower levels of histone deacetylase
activity in these assays were the result of less efficient
expression of Mad proteins, as determined by gel shift
analysis (data not shown); this is likely to be due to differ-
ences in transfection efficacies.
Mad proteins are potent inhibitors of cell growth. To deter-
mine whether Sin3B and HD1 can modulate Mad1 func-
tion in vivo, we carried out colony formation assays in
Saos-2 cells. The expression of Mad1 alone reduced the
number of colonies two-fold, whereas the expression of
Mad1Pro — a variant which has a mutation in the Sin3-
interaction domain and which does not bind Sin3 [17] —
had little effect (Fig. 4). The expression of Sin3B alone
(Fig. 4) or HD1 alone (data not shown) did not reduce the
number of colonies significantly, whereas the coexpression
of Sin3B and HD1 caused a two-fold reduction in the
number of colonies. When Sin3B and Mad1 were co-
expressed, the inhibitory effect of Mad1 was relieved
partially, possibly because the overexpressed Sin3B
sequesters endogenous HD1 or Rpd3-related enzymes.
However, the inhibitory effect of Mad1 was enhanced by
HD1, and, more significantly, by HD1 together with
Sin3B. These results suggest that the efficient recruitment
of histone deacetylase activity is relevant for the ability of
Mad1 to inhibit cell growth. By contrast, the combination
of Mad1Pro, Sin3 and HD1 did not show higher inhibition
than Sin3B and HD1 alone, emphasizing the importance of
the interaction between Mad1 and Sin3B/HD1. 
Mad1 efficiently inhibits serum-induced S-phase entry in
fibroblasts when microinjected into resting cells (A.M., J.
Mertsching, S.H., A.S., C. Cerni, M. Henriksson and B.L.,
unpublished observations). In this assay, Mad1 exerts its
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Figure 1
Co-immunoprecipitation of Max, Sin3B and HD1 with Mad1. COS7
cells were transiently transfected with the expression plasmids
pSP-max p22, pCMV-mad1, pCMV-sin3B and pCMV-HD1. After
metabolic labelling with 35S-methionine/cysteine, cells were lysed in
Frackelton buffer and 1/10 of the lysate was immunoprecipitated with
the indicated antibodies or with pre-immune serum (lanes 1–5). For
co-immunoprecipitations, half of the lysate was immunoprecipitated
with anti-Mad1 C19 (lane 6). Proteins bound to Mad1 were released in
AB buffer and re-precipitated with the indicated antibodies (lanes
7–10). The precipitated proteins are indicated on the left and the posi-
tions of molecular weight markers on the right.
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Recruitment of histone deacetylase activity by
Mad1. (a) COS7 cells were transiently
transfected with expression plasmids for Max
p22, Mad1, Mad1∆BR, Mad1∆N, Mad1∆C,
Sin3B and HD1, as indicated. Mad1-specific
immunocomplexes from Frackelton cell lysates
were obtained with monoclonal antibodies 5F4
or 5C9 and assayed for histone deacetylase
activity. Background activity was arbitrarily set
as 1. (b) Recognition of COS7 cell-expressed
Mad1, Mad1∆N and Mad1∆C by the different
Mad1 antibodies on western blots. (c) Mad1-
specific antibodies recognize native, DNA-
binding competent Mad1/Max complexes. The
indicated Mad proteins and Max were co-
expressed in COS7 cells and analysed by
electrophoretic mobility shift assay. Control
refers to extracts from vector transfected cells.
Supershifted bands are indicated by
arrowheads. The free probe was run off the gel.
inhibitory effect until late in G1. Therefore we tested
whether histone deacetylase activity was required for
S-phase inhibition. Resting NIH3T3-L1 cells micro-
injected with Mad1-expression plasmids were stimulated
with serum and were treated  in mid-G1 with or without
TSA. Whereas more than 90% of Mad1-expressing cells
were unable to enter S-phase, TSA treatment resulted in a
significant fraction of Mad1-positive cells that were able to
progress into S-phase (Fig. 5). TSA had no effect on
S-phase entry of control cells under the conditions used.
This finding suggests that histone deacetylase activity is
important for Mad1 to block progression into S-phase,
consistent with the observation that Mad1∆N, which lacks
the Sin3-interaction domain, does not inhibit entry into
S-phase (A.M., J. Mertsching, S.H., A.S., C. Cerni, M.
Henriksson and B.L., unpublished observations). 
Discussion
Here, we have shown that the Mad1/Max complex
interacts with Sin3B in vivo, and that the Max/Mad1/Sin3B
trimeric complex can bind HD1. This tetrameric complex
has histone deacetylase activity. We have therefore estab-
lished a link between sequence-specific DNA-binding
proteins and a histone deacetylase. The effects of Sin3B
and HD1 on the ability of Mad1 to inhibit colony forma-
tion, and of TSA to overcome the Mad1-induced S-phase
block, provide evidence for the biological relevance of
histone deacetylase recruitment by Mad proteins. We
suggest that the negative regulation of cell growth by Mad
proteins is, at least in part, the result of bringing histone
deacetylase activity to promoters, which in turn leads to
structural and/or functional alterations of nucleosomes and
ultimately to Mad-specific repression of gene transcription.
The available evidence suggests that Myc proteins affect
cell growth by regulating the expression of specific genes
[3]. The antagonistic effects of Mad proteins on Myc func-
tion may therefore at least in part involve the modulation
of the same genes. Whereas Myc activates the expression
of genes which contain Myc-specific E-boxes, Mad pro-
teins may inhibit such genes. The recruitment of histone
deacetylase activity, as well as other lines of evidence (for
discussion, see [3]), suggest that the transcriptional repres-
sion mediated by Mad is not likely to result from simple
competition between Myc/Max and Mad/Max complexes
for binding sites. Rather, by attracting histone deacetylase
activity to a promoter, histone deacetylation and com-
paction of chromatin may lead to a dominant inhibition of
transcription [22]. At present, this scenario is hypothetical
because no gene has been identified which is repressed by
Mad. So far, only the expression of a synthetic reporter
gene construct has been shown to be inhibited by Mad in
transient transfection experiments [9,11]. It is unclear
whether regularly positioned nucleosomes are formed on
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Figure 3
The tetrameric Max/Mad/Sin3B/HD1 complex
possesses histone deacetylase activity.
COS7 cells were transfected with expression
plasmids for the indicated proteins and
subsequently lysed in Frackelton buffer. (a)
Anti-Max and anti-Sin3B, but not pre-immune
(pre-im) serum immunoprecipitates, contain
histone deacetylase activity. Anti-HD1
immunocomplexes also possessed histone
deacetylase activity (data not shown). The
recruitment of histone deacetylase activity in
anti-Max immunoprecipitates was dependent
on the co-expression of both Mad1 and
Sin3B. Histone deacetylase activity was
inhibited by the addition of either sodium
butyrate or trichostatin A (TSA). (b) Mad4 can
mediate the association of histone
deacetylase activity with Max.
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transfected reporter gene constructs under such conditions
[55,56], and so histone deacetylase activity may not be
important for this type of repression; however, Mad pro-
teins without the Sin3-interaction domain are not able to
repress, suggesting that binding to Sin3 is still required. As
Sin3 has multiple domains for potential protein–protein
interactions, other proteins besides HD1 may be recruited
and may lead to inhibition of transcription. Thus, it will be
of utmost importance to identify Mad-regulated genes to
test the predictions made here. 
Our functional data are consistent with the concept that
such Mad-regulated genes exist and that histone deacety-
lase activity is relevant for the regulation of these genes
by Mad proteins (Figs 4,5). However, the modulation of
histone deacetylase activity in cells is likely to have many
different effects. Until specific Mad target genes can be
analysed and the role of histone deacetylase activity
determined in vivo, firm statements are difficult to make.
The use of TSA has clearly demonstrated that histone
deacetylase activity is important for cell growth [54]. It
has been shown that treatment with TSA results in a
reversible inhibition of cell growth by inducing a G1 and a
G2 arrest [57]. Consistent with this finding, we have also
observed that TSA can block S-phase entry of serum-
stimulated fibroblasts when the drug is added concomi-
tantly with serum (data not shown). Therefore we have
treated our cells between 7–10 hours after serum addition
with TSA. At this time, the cells are in mid to late G1
with the first cells entering S-phase 11 hours after serum
addition (data not shown). As the control cells were not
affected by this treatment, histone deacetylase activity
does not seem to be crucial for the G1-to-S phase transi-
tion. However, the Mad1-induced block can be over-
come, at least in part, by TSA treatment, suggesting that,
for the S-phase inhibiting function of Mad1, histone
deacetylase activity is necessary until late in G1.
Together with our finding that Mad1 inhibits entry into
S-phase until late in G1 (A.M., J. Mertsching, S.H., A.S.,
C. Cerni, M. Henriksson and B.L., unpublished observa-
tions), it is possible that genes which regulate the  G1-to-
S phase progression of the cell cycle or their regulators are
the target of Mad1 action. 
The recruitment of histone deacetylase activity to a
specific promoter through sequence-specific transcription
factors could influence the local acetylation status of core
histones. Several different models have been proposed for
the mechanism that links differential acetylation of the
amino-terminal tails of core histones to effects on gene
transcription [25]. These models include effects on
histone–DNA interaction, which may alter nucleosome
compaction and thereby regulate the access of proteins to
DNA or modify nucleosome mobility. Thus, a decreased
accessibility of other transcriptional regulators to a specific
promoter region could result in a dominant repression of
gene expression. The interaction of proteins with histones
may also be regulated by the degree and the specific
pattern of acetylation of histone tails. It has been shown
that the yeast silent information regulators Sir3 and Sir4
can bind to the amino termini of histone H3 and H4 [58].
Recruitment of such proteins could lead to the formation
of heterochromatin on larger chromosomal regions and
affect the expression of multiple genes. 
Sin3 proteins appear to function as adaptors that target
HD1 to Mad/Max complexes, but other targeting subunits
for HD1 may also exist. During the purification of this
enzyme, one subunit was identified as RbAp48, a protein
characterized previously as an interaction partner of the
retinoblastoma protein p105Rb [48,59]. Thus, RbAp48 may
recruit HD1 to p105Rb, which itself binds to the E2F class
of transcriptional regulators. E2Fs are important modula-
tors of the cell cycle and several different genes regulated
by these proteins have been identified [60–62]. It has
been suggested that p105Rb not only inhibits the transacti-
vation function of E2F factors but also represses actively
[63,64]. The dominant repressing effect exerted by the
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Figure 4
Inhibition of colony formation by Mad1. Sin3B
and HD1 enhance the Mad1-dependent
inhibition of colony formation in Saos-2 cells.
Saos-2 cells were transfected with expression
plasmids encodingthe indicated proteins;
neomycin-resistant colonies were selected
and counted after 30 days.
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E2F–p105Rb complex on the expression of genes contain-
ing E2F-binding sites may be the consequence of recruit-
ing histone deacetylase activity. Together, these findings
suggest that, through adaptor proteins and sequence-
specific transcription factors, HD1 and possibly other
histone deacetylases can be brought to specific genes and
influence their expression. 
Conclusions
Accumulating evidence suggests that histone acetylation
plays an important role in the regulation of gene transcrip-
tion. With the identification and characterization of HATs
and histone deacetylases, the enzymes involved can now
be studied. An important question is how HATs and
histone deacetylases are targeted to specific promoters.
Here, we provide evidence for a complex composed of the
sequence-specific DNA-binding complex Mad/Max, the
adaptor Sin3B and the histone deacetylase HD1. This
complex possesses histone deacetylase activity and
appears to be of functional relevance. Our findings also
imply that active HD1 can be targeted to promoters that
contain Myc E-boxes. 
Materials and methods
Expression plasmids
The plasmids pSP-max p22, pSP-mad1, pCMV-mad1, pCMV-mad1∆N
and pCMV-mad1∆C have been described previously [14]; pSP-
mad1∆BR, pSP-mad1Pro and pSP-mad4 were provided by R. Eisen-
man and the mad coding regions were subcloned into the pCMV
vector. A murine cDNA encoding HD1 was cloned as an interleukin-2
inducible gene (S. Bartl, J. Taplick, G. Lagger, H. Khier, K. Kuchler and
C.S., unpublished). Murine HD1 has 99% identity to human HD1, 84%
to murine Rpd3 and 58% to yeast RPD3 ([48,49,65] and S. Bartl, J.
Taplick, G. Lagger, H. Khier, K. Kuchler and C.S., unpublished). HD1
was tagged with a Myc epitope (9E10) and cloned into pCMV or
pBabe vectors (S. Bartl, J. Taplick, G. Lagger, H. Khier, K. Kuchler and
C.S., unpublished). A cDNA encoding murine Sin3B (from R. Eisen-
man) was cloned into pCMV. The expression of all constructs was
verified by western blotting and by immunoprecipitation (see Fig. 1 and
data not shown).
Cell culture and transfections
COS7, Saos-2 and NIH3T3-L1 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% FCS at
37°C, 5% CO2. Transfections were carried out using the calcium phos-
phate coprecipitation technique [66]. For the colony formation assays,
a total of 20 mg of the indicated combinations of expression plasmids
(pSP-mad1, pSP- mad1Pro, pBabe-HD1, pCMV-sin3B) or the respec-
tive control vectors were transfected into Saos-2 cells together with a
neomycin resistance plasmid. For each individual experiment, cell
cultures  were split into at least triplicate dishes after 24 h. After 48 h,
0.5 mg ml–1 G418 was added and colonies were stained after 30 days. 
Antibodies
Monoclonal antibodies were generated by immunizing Wistar rats with
a bacterially expressed glutathione-S-transferase–Mad1 fusion protein.
Monoclonal antibodies 5C9 and 5F4 recognize Mad1 specifically. The
polyclonal anti-Max serum 85 and the corresponding pre-immune
serum have been described previously [14]. The antiserum recognizing
HD1 will be described elsewhere (S. Bartl, J. Taplick, G. Lagger, H.
Khier, K. Kuchler and C.S., unpublished). Polyclonal antibodies recog-
nizing Mad1 and Sin3B were purchased from Santa Cruz (C-19 and
AK12, respectively). Rabbit anti-mouse antibodies and Cy3-labelled
secondary antibodies were from Jackson Immuno Research Laborato-
ries. An FITC-coupled monoclonal antibody recognizing BrdU was
obtained from Boehringer Mannheim.
Metabolic labelling and immunoprecipitations
For metabolic labelling, COS7 cells were transiently transfected with
pCMV-expression plasmids. Cells were labelled in methionine/cysteine-
free medium with 0.3 mCi 35S-Met/Cys-Translabel (ICN) per ml for
40 min at 37°C. The cells were then lysed in Frackelton buffer (10 mM
Tris-HCl, pH 7.05, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM
NaF, 5 mM ZnCl2, 100 mM Na3VO4, 1% Triton X-100, 1 mM PMSF,
5 U ml–1 a2-macroglobulin, 2.5 U ml–1 pepstatin, 2.5 U ml–1 leupeptin,
0.15 mM benzamidin, 2.8 mg ml–1 aprotinin), vortexed and cleared by
centrifugation. Max was immunoprecipitated with the polyclonal serum
85, Mad1 with the polyclonal antibody C-19 or with monoclonal
antibodies 5C9 or 5F4, Sin3B with the polyclonal antibody AK12 and
HD1 with a polyclonal serum, as described [67]. Briefly, for direct
immunoprecipitations, protein complexes were collected with protein A-
or protein G-Sepharose and washed under high stringent conditions:
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Figure 5
Trichostatin A overcomes the Mad1-dependent block of S-phase
progression. Resting fibroblasts were microinjected with pCMV-mad1
and serum-stimulated, and the number of S-phase cells was
determined. The cells were fixed and stained after 20–24 h. (a–d) Cells
stained for (a) BrdU, (b) Mad1or (c) DNA, and (d) the corresponding
phase contrast picture are shown. The cell located in the middle of the
frame expresses Mad1. (e) Summary of the microinjection experiments.
Trichostatin A (TSA) was added 7–10 h after serum stimulation. Cells
started to enter S-phase 11 h after addition of serum and more than
90% were BrdU-positive by 18 h (data not shown). 
0 20 40 60 80 100
% S-phase cells
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Control + TSA
Mad1
Mad1 + TSA
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(c)
(e)
(d)
twice with RIPA buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40,
1% deoxycholate, 0.1% SDS, 0.5% aprotinin), once with high salt buffer
(10 mM Tris pH 7.4, 2 M NaCl, 1% NP-40, 0.5% deoxycholate) and
finally with RIPA buffer. For co-immunoprecipitations, Mad1-containing
protein complexes were precipitated under low-stringent conditions in
Frackelton buffer. Co-immunoprecipitated proteins were released in AB
buffer (20 mM Tris pH 7.4, 50 mM NaCl, 1 mM EDTA, 0.5% NP-40,
0.5% sodium deoxycholate, 0.5% SDS, 0.5% aprotinin, 0.5% phenyl-
methylsulfonyl fluoride) and reprecipitated after a four-fold dilution into
Frackelton buffer. The immunocomplexes were washed under high-strin-
gent conditions as described above, boiled in sample buffer, separated
by 12.5% SDS–PAGE and visualized using a Phosphoimager.
Western blotting and electrophoretic mobility shift assays
The conditions for Western blotting have been described previously
[68]. The electrophoretic mobility shift assays will be reported else-
where (A.S., K. Bousset, E.K., M. Austen and B.L., unpublished obser-
vations). The CMD oligonucleotide has been described [69]. 
Immunoprecipitation–histone deacetylase assay
COS7 cells transiently transfected with pCMV constructs (except for a
pSP construct to express Max) were lysed in Frackelton buffer and pre-
cleared by centrifugation. The expression levels of the different Mad
proteins in these lysates were analysed by gel shift assays (data not
shown). Protein A- or protein G-Sepharose beads were incubated with
the respective antibodies prior to the addition of cell lysate (the equiva-
lent of 1/5 of a 10 cm dish). After incubation at 4°C for 1 h, the
immunocomplexes were washed twice in Frackelton buffer and once in
histone deacetylase assay buffer (20 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 10% v/v glycerol) [48]. The reactions were carried out in 30 ml
histone deacetylase assay buffer containing approximately 7.5 mg of in
vivo [3H]-acetate-labelled chicken reticulocyte core histones (corre-
sponding to approximately 5000–6000 cpm) [70,71] at 37°C for 2 h.
The reactions were stopped with 0.4M acetate/1M HCl and [3H]-
acetate was extracted with 1 ml ethylacetate and aliquots were
counted [72]. Where indicated, the reactions were performed in the
presence of either 2 mM Na-butyrate (Fluka) or 20 nM Trichostatin A
(Wako Chemicals GmbH). The basal histone deacetylase activity using
either lysates of untransfected cells or control antibodies resulted in the
release of 80–130 cpm. 
Microinjection
NIH3T3-L1 cells were grown on glass cover slips and serum-starved for
36 h. Cells were then microinjected with pCMV-mad1 and stimulated by
the addition of serum in the presence of 100 mM bromodeoxyuridine.
Progression into S-phase was monitored by anti-BrdU immunostaining.
Mad1-expressing cells were identified by staining with antibody C-19.
Trichostatin A (50 nM) was added 7–10 h after serum addition.
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